Switching patients from tetrabenazine to AUSTEDO

Reductions in TMC score, following overnight switch, observed through 8 weeks in switch cohort of an open-label, single-arm, multicenter study1

Reduction in TMC score, evaluated as an exploratory endpoint, observed at Weeks 1, 4, and 81,2

  • Dose adjustments were permitted after Week 11
  • At baseline, the mean dose of tetrabenazine was 42 mg/day. The mean doses of AUSTEDO were 20 mg/day (Week 1), 30 mg/day (Week 4), and 34 mg/day (Week 8)1

TMC Score Following Overnight Switch to AUSTEDO1

ARC-HD: TMC score at weeks 1, 4, and 8, following overnight switch from tetrabenazine, 1.86 point change in TMC score from baseline at Week 8. ARC-HD: TMC score at weeks 1, 4, and 8, following overnight switch from tetrabenazine, 1.86 point change in TMC score from baseline at Week 8.
Open-label, single-arm study design

The open-label, single-arm study was an extension study of patients from the placebo-controlled FIRST-HD trial. Patients in the switch cohort (N=37) switched overnight to AUSTEDO after ≥8 weeks of tetrabenazine. Patients were 40.5% female and 59.5% male. Average age was 52 years. Mean baseline TMC score was 12.5.1

Dosing for overnight switch from tetrabenazine

Overnight switch to AUSTEDO at approximately 50% of the tetrabenazine dose3

  • No washout required when switching patients with HD chorea from tetrabenazine
  • Patients may initiate AUSTEDO on the day following discontinuation of tetrabenazine
  • AUSTEDO is contraindicated in patients taking tetrabenazine

Recommended Initial Dose, After Switch From Tetrabenazine3

Chart showing recommended initial dose for AUSTEDO per current tetrabenazine dose. Chart showing recommended initial dose for AUSTEDO per current tetrabenazine dose.

After switching from tetrabenazine, the dose may be adjusted at weekly
intervals by 6 mg/day, following the dosing and titration schedule for AUSTEDO.3

TMC, total maximal chorea.

REFERENCES: 1. Data on file. North Wales, PA: Teva Neuroscience, Inc. 2. Frank S, Stamler D, Kayson E, et al. Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea. JAMA Neurol. 2017;74(8):977-982. 3. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ, Teva Neuroscience, Inc.